Hopes for single-dose Hepatitis C drug fade

Shares of Regulus fall but company, analysts still see promise 

LOS ANGELES (MarketWatch) — Shares of Regulus Therapeutics took it on the chin Monday after the biopharmaceutical company reported spotty results in tests for a drug designed to cure Hepatitis C with a single dose.

Regulus RGLS, +1.55%  shares dropped 10% to $15.15, as it appeared its drug, now designated as RG-101, will have to be accompanied by other treatments in many patients in order to cure Hepatitis C.

The company said RG-101 appeared to wipe out traces of the disease in four of 14 patients with a 2-milligram dose. This test was critical because it showed the drug’s ability to keep Hepatitis C at bay for 85 days. Patients who show no signs of Hepatitis C after 84 days are considered cured. 

Read more...

Labels: ,